Additionally, the 36-month beta value for LUCD is 1.27. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for LUCD is 41.07M and currently, short sellers hold a 3.26% ratio of that float. The average trading volume of LUCD on May 22, 2025 was 1.07M shares.
LUCD) stock’s latest price update
Lucid Diagnostics Inc (NASDAQ: LUCD) has seen a rise in its stock price by 2.31 in relation to its previous close of 1.30. However, the company has experienced a 3.91% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-05-15 that Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of implantable physiological monitor, and will soon launch first commercial partnership with major cancer center PAVmed seeking to leverage infrastructure and expand into biopharma sector; actively evaluating clinical and late preclinical stage assets Conference call and webcast to be held today, May 15 th, at 8:30 AM EDT NEW YORK, May 15, 2025 /PRNewswire/ — PAVmed Inc. (NASDAQ: PAVM) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and reported financial results for the quarter ended March 31, 2025. Conference Call and Webcast The webcast will take place on Thursday, May 15, 2025, at 8:30 AM and is accessible in the investor relations section of the Company’s website at pavmed.com.
LUCD’s Market Performance
Lucid Diagnostics Inc (LUCD) has experienced a 3.91% rise in stock performance for the past week, with a 3.91% rise in the past month, and a -10.74% drop in the past quarter. The volatility ratio for the week is 5.63%, and the volatility levels for the past 30 days are at 6.56% for LUCD. The simple moving average for the last 20 days is 6.55% for LUCD stock, with a simple moving average of 28.26% for the last 200 days.
Analysts’ Opinion of LUCD
Many brokerage firms have already submitted their reports for LUCD stocks, with Ascendiant Capital Markets repeating the rating for LUCD by listing it as a “Buy.” The predicted price for LUCD in the upcoming period, according to Ascendiant Capital Markets is $16 based on the research report published on December 27, 2021 of the previous year 2021.
Needham, on the other hand, stated in their research note that they expect to see LUCD reach a price target of $17. The rating they have provided for LUCD stocks is “Buy” according to the report published on November 08th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to LUCD, setting the target price at $21 in the report published on November 08th of the previous year.
LUCD Trading at -0.96% from the 50-Day Moving Average
After a stumble in the market that brought LUCD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.11% of loss for the given period.
Volatility was left at 6.56%, however, over the last 30 days, the volatility rate increased by 5.63%, as shares surge +3.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.02% upper at present.
During the last 5 trading sessions, LUCD rose by +3.91%, which changed the moving average for the period of 200-days by +76.98% in comparison to the 20-day moving average, which settled at $1.2483. In addition, Lucid Diagnostics Inc saw 62.45% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for LUCD
Current profitability levels for the company are sitting at:
- -15.06 for the present operating margin
- -0.87 for the gross margin
The net margin for Lucid Diagnostics Inc stands at -43.37. The total capital return value is set at 3.32. Equity return is now at value -1897.35, with -190.69 for asset returns.
Based on Lucid Diagnostics Inc (LUCD), the company’s capital structure generated 1.18 points at debt to capital in total, while cash flow to debt ratio is standing at -0.35. The debt to equity ratio resting at -6.56. The interest coverage ratio of the stock is 1393.53.
Currently, EBITDA for the company is -44.34 million with net debt to EBITDA at -0.8. When we switch over and look at the enterprise to sales, we see a ratio of 12.24. The receivables turnover for the company is 13.63for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.75.
Conclusion
In conclusion, Lucid Diagnostics Inc (LUCD) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
